Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

- Investigational Study Results Published in Journal of Clinical Oncology

Pave Way for Phase II Efficacy Trial -

NUTLEY, N.J., April 18 /PRNewswire/ -- A novel biweekly dosing schedule of Xeloda(R) (capecitabine) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the April 10, 2008 issue of the Journal of Clinical Oncology. The data showed that a seven-days-on/seven-days-off (7-on/7-off) regimen, called "dose dense," was generally well-tolerated up to 2,000 mg twice daily (4,000 mg/day), providing a potential alternative to the standard Xeloda dosing of 14 days on and seven days off (14-on/7-off).

"As we predicted using the Norton-Simon mathematical model -- the basis for the dose dense approach to therapy that was pioneered at MSKCC -- these results demonstrate that a biweekly regimen of capecitabine appears to be well-tolerated, at dosing levels that are higher than previously thought possible," said Tiffany A. Traina, M.D., a medical oncologist in the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and lead author of the study. "We're currently conducting later-phase trials to determine the efficacy of this 7-on/7-off dosing schedule."

Efficacy of the 7-on/7-off schedule using Xeloda is being determined in a Phase II clinical trial program in patients with advanced breast cancer and is also being tested in combination with Avastin(R) (bevacizumab).

Breast cancer is the most common cancer among women, other than skin cancer. According to the American Cancer Society (ACS), about 182,460 women in the United States will be found to have invasive breast cancer in 2008. Breast cancer is the second leading cause of cancer death in women, after lung cancer -- about 40,930 women will die from the disease this year. Metastatic breast cancer, or cancer that has spread from the breast to othe
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... LAVAL, Quebec , July 24, 2014 /PRNewswire/ ... VRX ) (TSX:VRX) announced today that it ... des marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... investors and to negatively influence the market price ... false and misleading statements regarding Valeant,s business despite ...
(Date:7/24/2014)... , Revenues from continuing operations of ... diluted EPS from continuing operations of $1.08, up 1.9% versus  ... of $0.92, 7% below prior year , Cash from ... , Full year 2014 revenues now expected to be up ... , Full year 2014 adjusted diluted EPS range narrowed to  ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... RIVER, Mass., May 9, 2012  Millstone Medical Outsourcing ... as Vice President of Quality Systems.  As a ... she will be responsible for managing the quality ... all quality associates, and working closely with customers ...
... Md., May 8, 2012 /PRNewswire-iReach/ -- Reimbursement ... device development and commercialization plan. For new product launches ... and quality of life benefits versus comparators to payers, ... ISPOR 2012 highlight these trends:  IMPACT OF ...
Cached Medicine Technology:Millstone Medical Outsourcing Hires New Vice President Quality 2Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies 2
(Date:7/24/2014)... Dr. Peter Oettgen, a member of the ... Boston, is the new Deputy Editor of Cardiology for ... experience in the field to the evidence-based, clinical reference ... Oettgen received his medical degree from the University of ... Tufts New England Medical Center. He is the Director ...
(Date:7/24/2014)... The European Omega 3 & Structured Lipids Market ... market in Europe with analysis and forecast of revenue. The ... 2012 to $989.91 million by 2018, at a CAGR of ... of the European omega 3 & structured lipids market report, ... also provides a glimpse of the segmentation of the European ...
(Date:7/24/2014)... Bethesda, MD (PRWEB) July 24, 2014 ... cells circulating in a patient’s blood has been achieved ... team at Massachusetts General Hospital. This is an important ... new approach to selecting the best treatment for each ... said Dr. Haber. “They often acquire new genetic features ...
(Date:7/24/2014)... The European air and missile defense radar market ... expected to register a CAGR of 8.06%, to reach $2.07 ... are the major spenders in the region with a number ... program and multinational (MEADS) program, which has been co-developed by ... of the Europe air and missile defense radar market report, ...
(Date:7/24/2014)... 24 July 2014. LSE Health and the European ... Cardiology (ESC) are pleased to announce the launch ... working in the field of cardiovascular sciences. , ... in Cardiovascular Sciences aims to equip cardiovascular specialists ... skills required to take on advisory, management or ...
Breaking Medicine News(10 mins):Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 2Health News:DynaMed™ Names Peter Oettgen, MD as Deputy Editor of Cardiology 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:LSE and ESC announce the launch of a new executive-style MSc 2
... in-patient rehabilitation are more likely to land back in ... poorly, show signs of depression and lack social support ... Branch (UTMB) at Galveston. Hospital readmission for older adults ... billion annually. , Among the first of such ...
... , FRIDAY, April 6 (HealthDay News) -- Children ... late may experience more severe symptoms than kids with autism ... These children also may be more likely to inflict ... more severe remain unknown, the study suggested it may have ...
... chemotherapy try to kill tumors by causing oxidative stress in ... protects cancer and other cells from these stresses could one ... them more susceptible to treatment. In the March 23 ... led by USC Professor Kelvin J. A. Davies demonstrated that ...
... FRIDAY, April 6 (HealthDay News) -- Patients with ... exposed to significant levels of radiation from diagnostic imaging ... data from 2,590 patients with gastrointestinal disorders between ... them had undergone diagnostic imaging tests such as computed ...
... News) -- Overuse injuries account for more than one-quarter of ... has found. Women -- especially those who played field ... of the overuse injuries (62 percent). For this study, ... collegiate athletes participating in 16 team sports at the University ...
... ,Airport security screening has increased substantially during the past ... According to the American Academy of Orthopaedic Surgeons ... were performed in the United States. A new ... Checkpoints: How Has Heightened Security Affected Patients," appearing ...
Cached Medicine News:Health News:Predictors identified for rehospitalization among post-acute stroke patients 2Health News:Predictors identified for rehospitalization among post-acute stroke patients 3Health News:Pregnancy Length May Influence Severity of Autism 2Health News:Scientists identify major source of cells' defense against oxidative stress 2Health News:Diagnostic Scans Tied to Radiation Risk for Gastro Patients 2Health News:Overuse Injuries Common Among Female College Athletes 2Health News:Clinical news alert from the American Academy of Orthopaedic Surgeons 2
Inquire...
The new Gemini EM microplate spectrofluorometer builds on the successful Gemini platform. This next generation reader incorporates all of the high performance features of the Gemini XS with new capab...
The Fluoroskan Ascent FL is equipped with both fluorometric and luminometric measurement technologies, providing a full coverage for fluorometric, glow and flash luminometric applications even in the...
... from Berthold Technologies, has been designed ... measurement modes to support academic and ... ratio measurements plus top and bottom ... for any researcher using fluorescence in ...
Medicine Products: